Sydney Lupkin

Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that’s not enough help.

The Food and Drug Administration has new tools to hold drug companies accountable for promises they make about medications. But the agency has yet to show its hand in using this new power.

Moderna said people without insurance will be able to get its COVID vaccine at no cost after the U.S. government bows out. But patients will have to use the company’s cumbersome assistance program.

An insulin maker is cutting its prices. Eli Lilly, one of the three makers of insulin products in the United States, is also making other moves toward affordability for people with diabetes.

Kids who need a hormone-blocking drug to prevent premature puberty have lost an off-label option. The company that makes the medicine, which is 1/8 the cost of the FDA-approved version, withdrew it.

Using the COVID vaccine “off-label” — whether that’s for booster shots or young children — may be tempting to some vaccine providers, but the CDC warns it could get them into trouble.

Merck traditionally has been a leader in vaccines but has not had success with a COVID-19 vaccine. It’s lending a hand to Johnson & Johnson, where production is running significantly behind schedule.

The Centers for Disease Control and Prevention released plans for the distribution of coronavirus vaccines. The logistical challenges could be as daunting as the scientific ones.

The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?

Federal government makes sixth and largest deal for coronavirus vaccine candidate as part of Operation Warp Speed.